BidaskClub lowered shares of Zoetis Inc. (NYSE:ZTS) from a hold rating to a sell rating in a research report sent to investors on Friday morning.

ZTS has been the subject of a number of other reports. Cantor Fitzgerald restated a buy rating and issued a $75.00 price objective on shares of Zoetis in a research report on Wednesday, September 6th. Hilliard Lyons assumed coverage on shares of Zoetis in a research report on Tuesday, June 20th. They issued a buy rating and a $77.00 price objective for the company. Zacks Investment Research lowered shares of Zoetis from a buy rating to a hold rating in a research report on Tuesday, July 4th. Goldman Sachs Group, Inc. (The) restated a neutral rating and issued a $62.00 price objective on shares of Zoetis in a research report on Monday, August 7th. Finally, Piper Jaffray Companies set a $73.00 price objective on shares of Zoetis and gave the company a buy rating in a research report on Friday, August 25th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and eleven have given a buy rating to the company’s stock. Zoetis currently has an average rating of Buy and an average target price of $65.44.

Shares of Zoetis (NYSE:ZTS) remained flat at $63.75 during trading on Friday. 2,543,606 shares of the company traded hands. The stock has a market capitalization of $31.18 billion, a P/E ratio of 36.04 and a beta of 1.02. The stock’s 50-day moving average price is $63.41 and its 200-day moving average price is $60.49. Zoetis has a 12 month low of $46.86 and a 12 month high of $65.83.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, meeting analysts’ consensus estimates of $0.53. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The company had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.27 billion. During the same period last year, the business earned $0.49 earnings per share. Zoetis’s revenue was up 5.0% compared to the same quarter last year. Analysts predict that Zoetis will post $2.34 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Zoetis Inc. (ZTS) Downgraded to “Sell” at BidaskClub” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/10/07/zoetis-inc-zts-downgraded-to-sell-at-bidaskclub.html.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Thursday, November 9th will be paid a dividend of $0.105 per share. This represents a $0.42 annualized dividend and a dividend yield of 0.66%. The ex-dividend date is Wednesday, November 8th. Zoetis’s dividend payout ratio (DPR) is presently 23.73%.

Several hedge funds have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Zoetis by 16.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after purchasing an additional 230 shares during the last quarter. Guardian Life Insurance Co. of America grew its holdings in shares of Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock worth $102,000 after purchasing an additional 13 shares during the last quarter. Point72 Asia Hong Kong Ltd bought a new position in shares of Zoetis in the first quarter worth approximately $111,000. Harfst & Associates Inc. grew its holdings in shares of Zoetis by 16.1% in the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after purchasing an additional 260 shares during the last quarter. Finally, Almanack Investment Partners LLC. bought a new position in shares of Zoetis in the second quarter worth approximately $119,000. 93.20% of the stock is currently owned by hedge funds and other institutional investors.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.